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We investigated consequences of cardiac arrest on sarcolemmal and mitochondrial effects of ATP-sensitive potassium channel (KATP)
opener, P-1075, in Langendorff-perfused rat hearts. Depolarised cardiac arrest (24.7 mM KCl) did not affect glibenclamide-sensitive twofold
activation of rubidium efflux by P-1075 (5 AM) from rubidium-loaded hearts, but eliminated uncoupling produced by P-1075 in beating
hearts: 40% depletion of phosphocreatine and ATP, 50% increase in oxygen consumption, and reduction of cytochrome c oxidase.
Depolarized cardiac arrest by calcium channel blocker, verapamil (5 AM), also prevented uncoupling. Lack of P-1075 mitochondrial effects
in depolarized hearts was not due to changes in phosphorylation potential, because 2,4-dintrophenol (10 AM) reversed the [PCr]/[Cr] increase
and Pi decrease, characteristic of KCl-arrest, but did not restore uncoupling. In agreement with this conclusion, pyruvate (5 mM) increased
[PCr]/[Cr] and decreased Pi, but did not prevent uncoupling in beating hearts. A decrease in mean [Ca
2 +] in KCl-arrested hearts could not
account for lack of P-1075 mitochondrial effects, because calcium channel opener, S-( )-Bay K8644 (50 nM), and beta-agonist,
isoproterenol (0.5 AM), did not facilitate uncoupling. In contrast, in adenosine (1 mM)-arrested hearts (polarized arrest), P-1075 caused 40%
phosphocreatine and ATP depletion. In isolated rat liver mitochondria, P-1075 (20 AM) decreased mitochondrial membrane potential (DW)
by approximately 14 mV (demonstrated by redistribution of DW-sensitive dye, rhodamine 800) in a glibenclamide-sensitive manner. We
concluded that cell membrane depolarization does not prevent activation of sarcolemmal KATP by P-1075, but it plays a role in mitochondrial
uncoupling effects of P-1075.
D 2003 Elsevier B.V. All rights reserved.Keywords: ATP-sensitive potassium channel; KATP opener; P-1075; Oxidative phosphorylation; Cytochrome c oxidase; Oxygen consumption; Sarcolemmal
polarization; Rb+/K+ efflux
1. Introduction this state preserves intracellular PCr and ATP because ofActivation of sarcolemmal ATP-sensitive potassium
channels (s-KATP) results in stimulation of K
+ efflux from
the cardiomyocytes [1] and sarcolemmal membrane hyper-
polarization, when membrane potential is more negative
than resting potential; this reduces Ca2 + entry and may
cause cardiac arrest [2]. It is thought that cardiac arrest in0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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Based on patch-clamp experiments in giant fused
mitoplasts, it has been proposed that a second type of
KATP is present in the inner mitochondrial membrane [7].
It is believed that activation of mitochondrial KATP chan-
nels (m-KATP) would result in K
+ influx into mitochon-
drial matrix, its swelling, activation of K+/H+ exchanger,
partial mitochondrial membrane potential (DW) depolar-
ization and, correspondingly, a decrease in ATP synthesis.
Up to now, molecular correlate of m-KATP has not been
determined. However, m-KATP existence was indirectly
confirmed in a number of models measuring: (1) K+-
dependent fluorescence in mitochondrial membrane frac-
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mitochondrial membrane-enriched lipid bilayers [8–10],
(3) mitochondrial swelling [11], (4) uncoupling induced
by KATP openers in isolated mitochondria [12,13] and
cardiomyocytes [14], and (5) binding of a KATP blocker,
glibenclamide, to inner mitochondrial membrane [15], al-
though validity of some of the indirect methods has recently
been questioned [16–19]. Recently, a sulfonylurea-binding
subunit (SUR2) and pore-forming subunits (Kir6.1 and
Kir6.2) of s-KATP were co-localized with mitochondria in
rat ventricular myocytes using anti-s-KATP subunit-specific
antibodies [20].
A pinacidil derivative, P-1075 [21], activates recom-
binant s-KATP [22,23]. P-1075 also binds with high
affinity to myocardial membrane preparations (containing
sarcolemmal and mitochondrial membranes) in MgATP-
dependent and glibenclamide-sensitive manner [24]. Re-
cently we have demonstrated that P-1075 (5 AM) stim-
ulated efflux of a K+ congener, rubidium (Rb+), from
Rb+-preloaded Langendorff-perfused beating rat hearts
more than twofold and induced cardiac arrest [25].
However, P-1075 also induced depletion of PCr and
ATP, stimulation of respiration, and reduction of cyto-
chrome c oxidase, indicating uncoupling of oxidative
phosphorylation [25,26]. These sarcolemmal and meta-
bolic effects of P-1075 were glibenclamide- and HMR
1098- (a cardioselective derivative of glibenclamide)
[25,26] sensitive. Metabolic uncoupling induced by P-
1075 is consistent with activation of putative m-KATP.
However, there is a controversy surrounding intracellular
specificity of P-1075. In quiescent rabbit cardiomyocytes,
P-1075 did not cause uncoupling, assessed by monitoring
oxidation of mitochondrial flavoproteins and, thus, was
proposed to have sarcolemmal specificity [27,28]. How-
ever, cardiomyocytes in cell culture and in situ are not
equivalent in several aspects. In non-beating cardiomyo-
cytes, sarcolemmal membrane potential as well as cyto-
solic and mitochondrial calcium concentrations do not
fluctuate [29], and energetic demands are drastically
diminished, resulting in resistance to metabolic inhibition.
We arrested rat hearts to investigate how cessation of
heartbeats may affect sarcolemmal and mitochondrial
effects of P-1075. Surprisingly, we found that cardiac
arrest in a depolarized form (induced by hyperkalemia or
verapamil) eliminated mitochondrial effects induced by P-
1075, while cardiac arrest in a polarized form (induced
adenosine) did not. However, hyperkalemic arrest did not
affect activation of Rb+ efflux by P-1075, implying that
s-KATP were activated in KCl-arrested hearts without
having an effect on mitochondrial uncoupling. In addi-
tion, in isolated rat liver mitochondria, P-1075 (20 AM)
slightly, but significantly, decreased DW by approximately
14 mV (demonstrated by redistribution of a DW-sensitive
dye, rhodamine 800). This decrease was glibenclamide-
sensitive, which is consistent with activation of putative
m-KATP.2. Methods
The investigation conforms with the ‘‘Guide to the Care
and Use of Experimental Animals’’ published by the Cana-
dian Council on Animal Care (Ottawa, ON, 1993).
2.1. Reagents
Glibenclamide, dimethylsulfoxide (DMSO), 2,4-dinitro-
phenol (DNP), ethylene glycol bis-(h-aminoethyl ether)
N,N,NVNV-tetraacetic acid (EGTA), DL-glutamic acid, K-
gluconate, carbonyl cyanide 4-trifluoromethoxyphenyl
hydrazone (FCCP), N-2-hydroxyethylpiperazine-NV-2-etha-
nesulfonic acid (HEPES), isoproterenol, Mg-ATP, RbCl,
sodium pyruvate, succinic acid, and verapamil were pur-
chased from Sigma (St. Louis, MO, USA). Adenosine and
S-( )-Bay K8644 were purchased from Research Bio-
chemicals International (Natick, MA, USA). P-1075 was
synthesized in Bristol-Myers Squibb (BMS) Pharmaceutical
Research Institute laboratories to be used for internal and
collaborative use by BMS. Stock solutions of P-1075 and
glibenclamide were prepared in DMSO and further diluted
in water. Rhodamine 800 (also known as MitoFluor Far Red
680) was purchased from Molecular Probes (Eugene, OR,
USA).
2.2. Heart perfusion
Male Sprague–Dawley rats (320–370 g) were anesthe-
tized with pentobarbital solution (120 mg/kg) intraperito-
neally. The hearts (1.4–1.7 g) were quickly removed and
perfused in a Langendorff mode with phosphate-free
Krebs–Henseleit buffer (KHB) containing (in mM): 25
NaHCO3, 118 NaCl, 4.7 KCl, 1.75 CaCl2, 1.2 MgSO4,
0.5 EDTA, and 11 glucose aerated with a mixture of 95% O2
and 5% CO2 to keep pO2 at 500–600 mm Hg and pH at 7.4
at 36 jC. A group of hearts was perfused with high-
potassium KHB, in which 20 mM KCl was added. KHB-
Rb had the same composition as KHB, except for K+, which
was substituted with Rb+ by 50%.
Following the placement of a left ventricular apical
drain, a latex balloon was inserted through the mitral valve
into the left ventricular cavity and filled with H2O. The
balloon was connected to a Statham P23Db pressure trans-
ducer and to a Digi-Med Model-210 heart performance
analyser (Micro-Med, Louisville, KY, USA) to monitor
heart rate (HR), left ventricular systolic pressure (LVSP),
left ventricular end-diastolic pressure (LVEDP), and perfu-
sion pressure (PP). Pressure-rate-product (PRP), calculated
as developed pressure (LVSP minus LVEDP) multiplied by
HR, was used as an index of mechanical work. The
coronary flow rate was monitored using an ultrasonic blood
flow meter (Transonic Systems Inc. Ithaca, NY, USA), and
PP was measured continuously through the catheter con-
necting the aortic line and the second pressure transducer.
Following stabilization period, the hearts were perfused at a
O. Jilkina et al. / Biochimica et Biophconstant flow of 13–15 ml/min to provide the desired
concentration of drugs during infusion. Typical baseline
parameters were: HR, 270 beats/min (no pacing); LVSP,
100; LVEDP, 7; PP, 70 mm Hg.
2.3. Experimental protocols
The protocols are presented as schematic diagrams on
Fig. 1. In all 31P-NMR protocols, three initial 4-min 31P
spectra were acquired and used as a baseline. After that, in
beating hearts, P-1075 (5 AM) was infused for 20 min (five
4-min 31P-NMR spectra acquired), followed by a 16-min
recovery period (four additional 31P-NMR spectra). In the
groups of beating hearts treated with P-1075 in combination
with other drugs, the drugs (5 AM verapamil, 5 mM
pyruvate, 1 mM adenosine) were infused for 8 min prior
to P-1075 and then for additional 20 min, simultaneously
with P-1075. In experiments involving potassium-arrested
hearts, following the acquisition of three baseline spectra,
the perfusion was switched to high-potassium KHB and two
4-min spectra were acquired before drug treatment. The
drugs (5 AM P-1075, 10 or 50 AM DNP, 50 nM S-( )-Bay
K8644, 0.5 AM isoproterenol, or 1 mM adenosine) were
infused for 40 min (Fig. 1). No drugs were infused in
control hearts.
In 87Rb experiments, all hearts were loaded with Rb+ by
perfusing with KHB-Rb for 30 min. Rb+ efflux was initiated
by switching to a Rb+-free normokalemic or high-potassium
KHB, containing P-1075 (5 AM) or no drugs (Fig. 1).
In optical spectroscopy and oxygen consumption experi-
ments with P-1075, the protocols were similar to those used
in 31P-NMR experiments (Fig. 1).Fig. 1. Perfusion protocols used for 31P-NMR and optical spectroscopy (A) and 87R2.4. NMR spectroscopy
NMR experiments were performed using a Bruker AM-
360 WB spectrometer equipped with a 20-mm Morris
Instruments broadband probe placed in a wide bore vertical
8.4-T magnet. The 23Na signal (95.25 MHz) from the heart
and surrounding bath was used for shimming. 31P-NMR
spectra were acquired at 145.8 MHz using a 35-As pulse
length (60j flip angle), 1.8-s recycle time and 4-min
resolution time. The sweep width was 10 kHz, memory
size, 4 K data points, line broadening factor, 20 Hz. Baseline
correction and peak amplitude measurements were done
using 1D WINNMR (Bruker) computer program. The
heights of the PCr and ATP peaks prior to interventions
were set as 100%. A capillary containing 10 Al of 1 M
solution of phenylphosphonic acid was used as a reference
in 31P-NMR protocols. 87Rb-NMR spectra were acquired at
117.8 MHz every 2 min using a spectral sweep width of 18
kHz, a recycle time of 10 ms, and a pulse duration of 55 As
(90j flip angle). Memory size was 512 data points. Line
broadening factor was 150 Hz. To minimize the signal from
the extracardiac and extracellular 87Rb, a suction line was
placed at the bottom of the NMR tube. A 10-Al capillary
containing 1 M RbCl and 5 M KI was used as a reference in
87Rb-NMR protocols.
2.5. Kinetics of Rb+ efflux
Rb+ efflux rate constant (k) was calculated as described
previously [30], as a slope from a linear portion of a
semilogarithmic plot (natural logarithm of Rb+ peak inten-
sity, a.u., versus time, min) using a linear regression method.
ysica Acta 1618 (2003) 39–50 41b-NMR spectroscopy (B). Values above the bars represent time in minutes.
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(first 4 min of the efflux) were discarded.
2.6. Myocardial absorbance measurements
Optical absorbance was measured using a spectrometer
built by Control Development (South Bend, IN, USA) and
equipped with Optical Spectrograph Card Instrument Driver
Software, version 3.0 F, produced by the same company.
The spectrometer was equipped with a bifurcated fiber-optic
cable. One end of the cable was connected to a source of
white light (Fiber Optic Illuminator, model 77501, Oriel
Instruments, Stratford, CT, USA), while a second end
terminated at the detector. The individual fibers of the cable
were combined into a common probe tip that was in a direct
contact with a left ventricle. Non-gated spectra were ac-
quired in the range 400–1000 nm every 30 s (60 scans).
Spectral data were processed using Grams/32 Version 4.11
computer program (Galactic Industries Corp, USA).
2.7. Oxygen consumption
An aliquot of the perfusate entering a heart was taken as
an arterial sample. Venous effluent was collected from the
cannulated right atrium. The oxygen content ( pO2, mm Hg)
in the samples was measured at approximately 7-min
intervals using Novastatprofile-Plus-9 (Nova Biomedical,
MA, USA). The rate of O2 consumption (VO2, Amol min 1
g 1) was calculated as a product of the difference in pO2
between the arterial and venous samples, and the coronary
flow, normalized to the wet heart weight.
2.8. Measurements of membrane potential (DW) in rat liver
mitochondria
Mitochondria were isolated as described elsewhere [31].
Mitochondrial preparation was suspended in the medium
containing 20 mM HEPES-Na (pH 7.2), 120 mM KCl and
1 mM EGTA to bring the concentration to 30–50 mg of pro-
tein/ml and stored on ice. Mitochondrial protein was deter-
mined by bicinchoninic acid assay using Sigma kit BCA-1.
Mitochondrial oxygen consumption was measured using
Clark-type oxygen electrode (Yellow Springs Instruments,
OH, USA) at 30 jC in the medium containing 20 mM
HEPES-Na (pH 7.2), 20 mM KCl, 100 mM K-gluconate
and 1 mM EGTA. Glutamate-Na (5 mM) + 5 mM malate-Na
or 5 mM succinate-Na was used as oxidizable substrates.
Following stabilization of state 2 respiration, 0.3 mM
MgADP was added to stimulate respiration (state 3), which
returned to the level close to state 2 (state 4) upon comple-
tion of ADP phosphorylation. FCCP (1 AM) was added at
the end of the assay to obtain uncoupled respiration rate.
The respiration rates were expressed in nmol O2/min mg
and the respiratory control index (RCI) as a ratio of state 3
to state 2 respiration rate. RCI was 6.9F 1.11 (n = 5) with
glutamate +malate and 4.52F 0.49 (n = 4) with succinate.Membrane potential was estimated using an optical
potentiometric probe, rhodamine 800. Mitochondria (0.2
mg/ml) were incubated in 1 ml of aerated medium contain-
ing 20 mM HEPES-Na (pH 7.2), 20 mM KCl, 100 mM K-
gluconate, 1 mM MgSO4 and 1 mM EGTA at 30 jC with 5
AM rhodamine 800 for 5 min in the presence of 5 mM
MgATP and oxidizable substrates (5 mM glutamate-Na + 5
mM succinate-Na). FCCP (1–10 AM), P-1075 (20 AM), and
glibenclamide (5 AM) were added simultaneously with
rhodamine 800. The reaction mixture in open scintillation
vials (25-mm diameter) was continuously shaken to provide
adequate aeration. Following 5-min incubation, the mixture
was rapidly cooled and centrifuged for 5 min at 10,000 g.
Mitochondrial pellet was extracted by 1-ml 95% EtOH and
rhodamine 800 content was measured in the supernatant and
extract spectrophotometrically (Beckman DU 650 spectro-
photometer, Beckman Instruments (Canada) Inc, Missi-
sauga, ON, Canada) at 680–685 nm (e= 99 mM 1
cm 1). We assumed that the equilibrium distribution of
the dye between the external space (e) and matrix (m) obeys
the Nernst law with the correction for membrane binding
[32]: Mitochondrial dye content (MDC),
MDC=½Ce ¼ ðVmatrix þ P  VmembrÞ  expðDW  F=RTÞ;
ð1Þ
where [C]e is an equilibrium supernatant concentration (C),
Vmatrix and Vmembr are matrix and membrane volumes,
respectively, P is a partition coefficient between the matrix
and membrane, F, Faraday constant, R, gas constant and T,
an absolute temperature.
In the presence of a modulator X (where X is FCCP, or P-
1075, or glibenclamide)
ðMDC=½CeÞx ¼ ðVmatrix þ P  VmembrÞ
 expðDWx  F=RTÞ ð2Þ
Thus
ðDWx  DWcontrolÞ ¼ 59½logðMDC=½CeÞcontrol
 logðMDC=½CeÞx ðin mVÞ ð3Þ
assuming that the matrix volume and dye partition coef-
ficient do not change significantly in the presence of
modulators.
2.9. Calculations of [ATP]/[ADP] and [PCr]/[Cr]
These parameters were calculated as described previous-
ly [33] according to the following formula
ð½ATP=½ADPÞ=ð½ATP=½ADPÞ0
¼ ð½PCr=½CrÞ=ð½PCr=½CrÞ0  antilog DpHi ð4Þ
where subscript 0 denotes initial values.
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ratio of [PCr]/[Cr] was calculated from the following
formulas, where the levels of high-energy phosphate metab-
olites were expressed as % of the initial values
½PCr þ ½Cr ¼ ½PCr0 þ ½Cr0 ¼ 100% ð5Þ
½PCr=½Cr ¼ ½PCr=ð100 ð½PCr  ½PCr0ÞÞ ð6Þ
Assuming that pHi did not change considerably, a relative
change in [ATP]/[ADP] could be substituted with [PCr]/[Cr].
2.10. Statistics
ANOVA (single factor) was used for data comparison.
Differences were considered statistically significant when
P < 0.05. Data are presented as meansF S.E.3. Results
3.1. Activation of Rb+/K+ efflux by P-1075 in beating and
KCl-arrested rat hearts
Elevated (24.7 mM) potassium induced sarcolemmal
membrane depolarization resulting in cardiac arrest [2]. P-
1075 (5 AM) stimulated the Rb+/K+ efflux in beating as
well as KCl-arrested rat hearts (Fig. 2). At a lower con-
centration (1 AM), P-1075 also stimulated the Rb+ effluxFig. 2. Activation of Rb+ efflux by P-1075 from beating and potassium-arrested pe
Rb normokalemic buffer for 30 min. Rb+ washout was initiated by switching perfu
arrested (closed symbols) rat hearts. Rb+ efflux measured in the presence (trianglesmarginally; however, the change did not reach statistical
significance [25]. The degree of stimulation did not depend
on the sarcolemmal polarization state, as the rate constant
of the Rb+ efflux in the beating hearts was similar to that in
the KCl-arrested hearts: kbeating = 0.087F 0.005 (n = 4),
karrested = 0.082F 0.002 (n = 5) min
 1. In drug-untreated
hearts, k = 0.040F 0.002 (n = 3) in the beating hearts, and
0.048F 0.002 (n = 4) min 1 in the KCl-arrested hearts.
Glibenclamide (5 AM) blocked Rb+ efflux stimulation by
P-1075 in beating [25] and KCl-arrested (k = 0.049F 0.001,
n = 3) hearts, which is consistent with activation of s-KATP
by P-1075.
3.2. Effects of P-1075 on high-energy phosphates and
cardiac function in beating and KCl-arrested hearts
Treatment of beating rat hearts with 5 AM P-1075 caused
cardiac arrest after, on average, 9 min, probably due to
sarcolemmal membrane hyperpolarization. After 20 min of
treatment, diastolic pressure increased from 5 to 60 mm Hg;
PCr and ATP were depleted by 40% (demonstrated by 31P-
NMR) (Table 1). The damage was irreversible, recovery was
poor; the hearts were fibrillating and trembling.
KCl-arrest resulted in an approximately 25% increase in
the PCr peak (f 80% average increase in [PCr]/[Cr] for all
KCl-arrested hearts, Table 2), and a decrease in the Pi peak
to the level that was not discernible with this method (Fig.
3). The [PCr]/[Cr] increase corresponds to a similar relative
increase in [ATP]/[ADP] under the conditions of KCl arrest,rfused rat hearts. The hearts were loaded with Rb+ by perfusion with KHB-
sion to Rb+-free KHB in beating (open symbols) and potassium (24.7 mM)-
) or absence (squires) of P-1075 (5 AM). Data are presented as meansF S.E.
Table 1
Modulation of P-1075 effects by verapamil, pyruvate, and adenosine under normokalemic conditions
Group [PCr]/[Cr] prior to
P-1075 infusion
PCr, % ATP, % LVEDP, mm Hg PP, mm Hg PRP, %
(1) Control, n= 5 1 93.2F 2.8 96.6F 3.9 5.6F 4.7 80.0F 6.0 101.5F 6.9
(2) P-1075, n= 7 1 60.3F 2.2 59.7F 4.6 60.7F 7.5 80.0F 4.6 0
(3) Verapamil/P-1075, n= 3 1.44F 0.17 96.7F 1.2 80.3F 5.0 27.5F 3.7 84.1F 6.0 0, except for
one heart: f 7%
(4) Pyruvate/P-1075, n= 3 1.44F 0.24 57.0F 3.9 47.5F 8.9 70.9F 1.3 93.7F 3.2 0
(5) Adenosine, n= 3 1.20F 0.12 96.3F 5.6 100.7F 2.5 17.7F 3.6 65.3F 4.3a 3.5F 2.2
(6) Adenosine/P-1075, n= 3 1.09F 0.23 63.4F 8.5 62.7F 3.7 61.8F 1.1 73.4F 1.5 0
P-1075 (5 AM) was infused for 20 min. Infusion of verapamil (5 AM), pyruvate (5 mM), or adenosine (1 mM) started 8 min prior to the infusion of P-1075 and
continued for additional 20 min, simultaneously with P-1075 (see protocols on Fig. 1A). The metabolic and functional parameters correspond to 16–20-min
perfusion with P-1075 (groups 2, 3, 4, and 6) or to the respective time point in the groups without P-1075 (groups 1 and 5). [PCr]/[Cr] values correspond to 4–
8-min treatment with verapamil (group 3), pyruvate (group 4), or adenosine (group 5 and 6). In groups 1 and 2 [PCr]=[Cr] before any treatment, by assumption
(see Methods). MeansF S.E. are presented.
a PP transitory declined from 70 to 60, then gradually increased to 65 mm Hg.
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[34]). Hyperkalemia on its own had very little adverse
effects on the hearts: after 52 min of high-potassium
perfusion, recovery was nearly complete.
To analyse mitochondrial effects of P-1075 under the
conditions of KCl-arrest, the hearts were perfused with a
high-potassium buffer for 8 min prior to P-1075 infusion, to
allow new equilibrium parameters be reached. P-1075 (5
AM) treatment time increased to 40 min to detect smaller (if
any) metabolic effects of P-1075, since energy expenditures
were drastically reduced in the arrested hearts. Addition of
P-1075 did not alter PCr and ATP levels in comparison to
drug-untreated KCl-arrested hearts (Fig. 3, Table 1). In
contrast, a classic mitochondrial uncoupler, DNP (50 AM),
that uncouples oxidative phosphorylation due to its proper-
ties as a protonophore [35] retained its ability to do so in the
KCl-arrested hearts (Table 2).
3.3. Effects of P-1075 on cytochrome c oxidase redox state
in beating and KCl-arrested hearts
Monitoring of myocardial 603-nm absorbance allows in
situ measurements of cytochrome c oxidase redox state thatTable 2
Effects of P-1075 and other drugs in KCl-arrested hearts
Group [PCr]/[Cr] prior Metabolic a
to drug infusion
PCr, %
(1) Control, n= 3 1.80F 0.49 118.6F 9.6
(2) P-1075, n= 3 2.18F 0.24 127.0F 5.4
(3) DNP (50 AM), n= 3 2.04F 0.43 35.7F 12
(4) DNP (10 AM), n= 3 1.41F 0.06 84.5F 4.4
(5) DNP (10 AM)/P-1075, n= 3 1.87F 0.63 83.8F 9.2
(6) Bay Ka, n= 3 1.57F 0.11 85.4F 4.1
(7) Bay K/P-1075, n= 4 1.98F 0.32 88.8F 9.2
(8) Isoproterenol/P-1075, n= 4 1.54F 0.23 95.0F 5.6
(9) Adenosine/P-1075, n= 3 1.70F 0.33 111.8F 3.9
Hearts were arrested with KHB containing 24.7 mM KCl. Eight minutes after per
( )-Bay K8644 (50 nM), isoproterenol (500 nM), or adenosine (1 mM), alone or
protocols on Fig. 1A). [PCr]/[Cr] was determined at 4–8 min of KCl treatment.
a S-( )-Bay K8644 denoted as Bay K.reflects changes in the rate of movement of redox equiv-
alents to cytochrome c oxidase [34]. Under normal meta-
bolic conditions when respiration is controlled by ADP
availability, level of reduction of electron carriers decreases
from the dehydrogenase (flavins) to the oxygen end (cyto-
chrome c oxidase). Uncouplers of oxidative phosphorylation
(DNP) release acceptor control accelerating electron flux
from the dehydrogenases to the cytochrome c oxidase; thus,
oxidizing flavins [14] and reducing cytochrome c oxidase
(Fig. 4A). Indeed, in beating hearts, on treatment with DNP
[26] and P-1075 (Fig. 4A), an increase in 603-nm absor-
bance was observed indicating that cytochrome c oxidase
became reduced. The increase was 30% of the level detected
during anoxia induced by complete cessation of perfusion
(Fig. 4B). Absorbance at the neutral wavelength did not
change, indicating a lack of artefacts associated with the
possible changes in light scattering [26]. The P-1075-in-
duced increase was transient, probably reflecting changes in
kinetic properties of cytochrome c oxidase and Krebs cycle
following approximately 10-min exposure to P-1075 (Fig.
4B and C). In contrast, in potassium-arrested hearts, 603-nm
absorbance decreased, reflecting oxidation of cytochrome c
oxidase due to increased oxygen accessibility. This decreasend functional parameters corresponding to 36–40 min of drug treatment
ATP, % LVEDP, mm Hg PP, mm Hg PRP, %
93.0F 5.0 31.5F 3.5 94.1F 2.0 0
92.8F 2.6 36.9F 9.2 97.6F 6.5 0
.5 40.8F 9.0 68.7F 7.6 97.9F 0.9 0
92.6F 6.9 46.1F 6.2 114.4F 12.2 0
82.9F 2.2 57.3F 15.5 115.9F 11.8 0
82.4F 3.6 29.8F 14.2 168.8F 9.7 0
82.9F 4.6 49.5F 8.7 160.1F13.3 0
87.9F 2.2 3.7F 4.7 64.5F 4.2 30.9F 11.5
98.9F 7.1 33.9F 1.6 91.8F 7.8 0
fusion with high-potassium buffer, P-1075 (5 AM), DNP (10 or 50 AM), S-
in the combinations as described in the Table, was infused for 40 min (see
MeansF S.E. are presented.
Fig. 3. Inhibition of P-1075-induced mitochondria uncoupling by potassium arrest in perfused rat hearts. Representative 31P-NMR spectra of a beating heart
and KCl-arrested rat heart, both of them being treated with P-1075 (5 AM). The spectra are the sum of 116 acquisitions collected over 4-min periods before any
treatment (baseline), 4–8 min of KCl-arrest, and 16–20-min of P-1075 infusion. Pi, inorganic phosphate.
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starting of heartbeats (Fig. 4B and C). Addition of P-1075 to
the KCl-arrested hearts did not increase myocardial absor-Fig. 4. Effects of P-1075 on redox state of cytochrome c oxidase in beating a
representative rat heart before (solid line) and during (dash line) treatment with P
603-nm absorbance from a beating (top trace) and a potassium-arrested (bottom
global no-flow ischemia between 50 and 55 min of the protocol to calibrate the cha
potassium-arrested (diamonds, n= 4) rat hearts treated with P-1075 (5 AM). Databance at 603 nm (Fig. 4B and C), thus confirming that no
uncoupling by P-1075 took place under the conditions of
KCl-arrest.nd potassium-arrested rat hearts. (A) Top: myocardial absorbance from a
-1075 (5 AM). Bottom: difference between the spectra. (B) Time course of
trace) rat heart treated with P-1075. The beating rat heart was subjected to
nges caused by P-1075. (C) Pooled data for the beating (squares, n= 3) and
are presented as meansF S.E.
Biophysica Acta 1618 (2003) 39–503.4. Effects of P-1075 on cellular respiration in beating and
KCl-arrested hearts
We demonstrated earlier that oxygen uptake was elevated
by 50% in the P-1075-treated beating hearts [25]. KCl arrest
resulted in an almost twofold increase in the venous oxygen
concentration (Fig. 5A). Myocardial oxygen consumption
fell to approximately 30% of the baseline, due to a cessation
of heart beats and a decrease in ATP turnover (Fig. 5B). On
infusion of P-1075, venous oxygen concentration did not
decrease, and the rate of oxygen consumption did not
increase (Fig. 5).
3.5. Effects of changes in phosphorylation potential on
P-1075-induced uncoupling
We investigated if changes in phosphorylation potential
were responsible for the lack of mitochondrial effects of P-
1075 in KCl-arrested hearts. To reverse these changes, we
infused 10 AM DNP into the KCl-arrested hearts to slightly
uncouple oxidative phosphorylation and stimulate ATP
futile cycles and respiration. Following DNP infusion,
[PCr]/[Cr] ratio fell from nearly 2 to approximately 1,
becoming similar to that in beating hearts (not shown).
However, this change did not restore the uncoupling by P-
1075, as there was no difference in the PCr and ATP levels
between the potassium-arrested hearts treated with DNP + P-
1075 or DNP-alone (Table 2). Additional confirmation came
O. Jilkina et al. / Biochimica et46Fig. 5. The effects P-1075 (5 AM, n= 4) on venous oxygen pressure (A) and
oxygen consumption (VO2) rate (B) in the potassium-arrested rat hearts.
Venous effluent was collected from the cannulated right atrium, an arterial
sample was taken from the perfusion line close to the heart. Data are
presented as meansF S.E.from the experiments in beating hearts, where infusion of
pyruvate (5 mM) significantly increased [PCr]/[Cr] and
decreased Pi to an undetectable level, but did not prevent
depletion of high-energy-phosphates by P-1075 (Table 1).
3.6. Effects of variations in intracellular calcium on P-
1075-induced uncoupling
A calcium channel blocker, verapamil [36] (5 AM),
similarly to high potassium, stopped the hearts in a depo-
larized state [2], increased [PCr]/[Cr] and prevented deple-
tion of PCr and ATP by P-1075 (Table 1). This could imply
that a certain level of intracellular [Ca2 +] is required for the
uncoupling. However, the effects of verapamil were not due
to a decrease in mean cytosolic [Ca2 +], because an L-type
calcium channel opener, S-( )-Bay K8644 [37] (50 nM),
which increases [Ca2 +]i, did not facilitate the uncoupling
effect of P-1075 in potassium-arrested hearts (Table 2).
Elevated PP in S-( )-Bay K8644-treated hearts (Table 2)
was a manifestation of [Ca2 +] increase in vascular smooth
muscle cells. Similarly, a structurally unrelated calcium
channel activator, FPL 64176 [37] (500 nM), did not
facilitate uncoupling by P-1075 in potassium-arrested hearts
(not shown).
To confirm that increased intracellular [Ca2 +] was not a
critical factor in mitochondrial uncoupling by P-1075, we
infused a h-adrenergic agonist, isoproterenol (0.5 AM) into
KCl-arrested hearts. Isoproterenol not only increases intra-
cellular [Ca2 +], but also stimulates signal transduction
pathways leading to activation of extracellular signal-reg-
ulated protein kinases (ERKs) and protein kinase A
[38,39]. Isoproterenol induced heartbeats and restored me-
chanical function of potassium-treated hearts to approxi-
mately 30% (Table 2). However, P-1075 did not cause a
decrease in PCr and ATP in KCl-arrested/isoproterenol-
treated hearts (Table 2).
3.7. Metabolic effects of P-1075 in a hyperpolarized
cardiac arrest
Since P-1075-induced uncoupling disappeared in KCl-
and verapamil-arrested hearts, we investigated the effects of
other forms of cardiac arrest. Adenosine (1 mM) induced
almost complete and reversible cardiac arrest presumably in
a polarized or hyperpolarized state [40] (Table 1). Occa-
sional escape heartbeats were observed and mechanical
function (PRP) was maintained at about 3% of baseline
(Table 1). PCr and ATP levels in adenosine-arrested hearts
were comparable to those in potassium- and verapamil-
arrested hearts (Tables 1 and 2). However, adenosine-arrest
did not prevent depletion of PCr and ATP caused by P-
1075 treatment (Table 1). Yet, P-1075 did not induce
uncoupling in KCl-arrested + adenosine-treated hearts (Ta-
ble 2), thus eliminating the possibility that adenosine-
initiated signal transduction cascades were critical for the
uncoupling.
Fig. 6. Effect of P-1075 on membrane potential in isolated liver
mitochondria. Mitochondria were incubated for 5 min in high K+ medium
at 30 jC with 5 AM rhodamine 800 in the presence of 1 AMFCCP (n= 11), 5
AM P-1075 (n= 11), 5 AM glibenclamide (n= 9), 5 AM P-1075 + 5 AM
glibenclamide (n= 8) and 0.3% DMSO (n= 9). Changes in the membrane
potential relative to the control are shown. Data are presented as
meansF S.D.
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liver mitochondria
Cardiac and liver mitochondria have similar biochemi-
cal characteristics. Presence of mito-KATP was demonstrat-
ed in both heart and liver mitochondria [7,8]. Therefore,
we used liver mitochondria to investigate the mitochondri-
al effects of P-1075. Incubation of 5 AM rhodamine 800
with liver mitochondria energized by ATP hydrolysis + res-
piration (glutamate + succinate) resulted in a drop of rho-
damine 800 concentration in extramitochondrial medium to
0.13F 0.02 AM due to strong binding of the dye to
mitochondria. Mitochondria accumulated 26.8F 2.4
(n = 7) nmol of rhodamine 800/mg protein. FCCP reduced
mitochondrial dye content 10-fold to 2.7F 0.04 nmol/mg
(n = 7) and increased rhodamine 800 concentration in the
external medium to 3.1F 0.32 AM (24-fold). These
changes in rhodamine 800 binding induced by FCCP
corresponded to depolarization of DW by 135F 9 mV
(Fig. 6). P-1075 (20 AM) slightly decreased DW by
13.6F 9.5 mV (n = 7). Glibenclamide (5 AM) completely
reversed the P-1075 effect, while glibenclamide alone did
not change DW. DMSO (0.3%) that was used for prepa-
ration of drug solutions had no effect on DW (Fig. 6).4. Discussion
4.1. Methodological considerations for in situ
measurements
We used three different noninvasive techniques to detect
mitochondrial uncoupling in intact rat hearts: (1) 31P-NMR,
(2) optical redox changes in cytochrome c oxidase, and (3)oxygen uptake measurements. 31P-NMR provides informa-
tion on inhibition of ATP synthesis/activation of ATP
hydrolysis; however, this method cannot distinguish be-
tween uncoupling and inhibition of electron transport/Krebs
cycle/glycolysis. Cytochrome c oxidase becomes reduced
during both hypoxia and uncoupling. However, stimulation
of VO2 indicated that P-1075-induced changes were due to
activation of mitochondrial electron transport rather than
other O2 consuming pathways.
Oxygen uptake rate is a crucial parameter, which
increases due to uncoupling or activation of cellular
ATPases, and decreases in a response to inhibition of
electron transport (e.g., hypoxia, blockade of dehydro-
genases) or deactivation of cellular ATPases (KCl-arrest).
P-1075 depressed cardiac contractility, which was initially
associated with indirect inhibition of myofibrillar ATPase
activity, probably due to reduced Ca2 + entry through
hyperpolarized sarcolemma. However, P-1075 could indi-
rectly activate Na+/K+ ATPase by increasing K+ turnover
rate, estimated as kRb efflux [K+]intracellVintracell (where,
[K+]intracell = 140 Amol/ml, Vintracell is intracellular volume
per gram of tissue = 0.5 ml/g), from 2.8 to 6.0 Amol K+/
min/g in beating hearts. Therefore, the rate of ATP
utilization by Na+/K+ ATPase increased from 1.4 to 3.0
Amol/min/g (stoichiometry of K+ transport per ATP used is
ATP/K+ = 0.5), which is only 8–17% of the basal ATP
turnover rate of 18 Amol/min/g ( = 6V(O2)). However,
glibenclamide-sensitive activation by P-1075 of other
ATPases, such as Ca2 + ATPase of sarcoplasmic reticulum
and sarcolemma, was unlikely. Furthermore, if there was
no uncoupling, P-1075-stimulated rate of oxygen uptake
(3.8 Amol/min/g [25]) and, therefore, the rate of ATP
synthesis (6V(O2)c 23 Amol/min/g) would not be limited
by O2 supply since pO2venous was 110 mm Hg [25], which
is still in the range of arterial pO2 in blood. In addition,
this rate of ATP synthesis was well below the maximal rate
of that observed in glucose-perfused hearts under normal
physiological conditions (>50 Amol/min/g wet weight
[41]). Therefore, it is unlikely that P-1075 effects were
mediated by increased cellular ATPase activity without
mitochondrial uncoupling.
Thus, taken together, these three parameters provided
unequivocal evidence of mitochondrial uncoupling. Because
P-1075-induced uncoupling was reversed by sulfonylureas
[25,26] any possible non-KATP-mediated effects of P-1075
were negligible. The question is whether the uncoupling
effects of P-1075 resulted from activation of sarcolemmal or
mitochondrial KATP or both.
4.2. Activation of s-KATP by P-1075 in situ
In rat hearts, P-1075 can activate s-KATP directly by
binding to sulfonylurea receptor of the channel and indi-
rectly by a decrease in [ATP]/[ADP] resulting from mito-
chondrial uncoupling [22,23,42]. The observation that the
rate of Rb+ efflux from KCl-arrested hearts, where P-1075
O. Jilkina et al. / Biochimica et Biophysica Acta 1618 (2003) 39–5048had no uncoupling effect, was the same as that in the
beating hearts is consistent with full activation of s-KATP
by 5 AM P-1075. This degree of activation makes P-1075
one of the most potent KATP openers available today. A
closely related compound, pinacidil [21], taken at 60-fold
higher concentration, activated the Rb+ efflux by only 20%
(Jilkina et al., unpublished observation).
It is possible that activation of s-KATP can contribute
towards the metabolic effects by P-1075. However, the link
between the activation of s-KATP and uncoupling of oxidative
phosphorylation is not currently understood. Elevated cyto-
plasmic Ca2 + can impair ATP production. KATP openers
hyperpolarize cardiomyocyte sarcolemma and, therefore,
decrease Ca2 + entry in isolated cells. However, in beating
hearts the situation is more complicated. First, cytosolic
[Ca2 +] fluctuates, and relations between membrane polariza-
tion, calcium oscillations, and cardioenergetics are not clear.
Second, for a long time it was recognised by electrophysiol-
ogists that there are clefts in the extracellular space (e.g., t-
tubules) where K+ concentration can be different from the
average extracellular one (for review see Ref. [43]). In
beating hearts, significant activation of K+ efflux by P-1075
may result in accumulation of K+ in the extracellular clefts,
local depolarization of cell membrane and increased Ca2 +
entry. In the KCl-arrested hearts, the extracellular K+ is
already high (24.7 mM) and, therefore, it buffers K+ increase
caused by activation of s-KATP channels. However, there are
no data to support this hypothesis. Interestingly, P-1075 is
known to have higher potency of activating SUR2B/Kir6.2
channels as opposite to SUR 2A/Kir6.2 [22], and it is the
SUR 2B subunits that were shown to co-localize strongly
with the t-tubules [20].
Hyperpolarized/polarized cardiac arrest per se should not,
theoretically, induce metabolic uncoupling [2–6]. Indeed, a
similar hyperpolarized arrest induced by adenosine did not
produce any deleterious effects on the cardiac metabolism
(Table 1). For these reasons, strictly the sarcolemmal origin of
metabolic effects of P-1075 seems to be unlikely.
4.3. Activation of m-KATP by P-1075 in situ
The metabolic effects of P-1075 can be readily explained
by its interaction with putative m-KATP. Indeed, in KCl-
arrested hearts, s-KATP were activated by P-1075, yet this
had no metabolic consequences. However, the factors that
either promoted interaction of P-1075 with m-KATP in polar-
ized hearts or blocked this interaction in depolarized hearts
remained elusive. KCl arrest causes a number of metabolic
and ionic changes: (1) an increase in the cytoplasmic [ATP]/
[ADP] and phosphorylation potential, (2) a decrease in mean
cytoplasmic [Ca2 +], (3) oxidation of mitochondrial cyto-
chrome c oxidase and reduction of NAD+ and dehydro-
genases [34,44]. The hypothesis that the uncoupling effect
was sensitive to different energetic status ([ATP]/[ADP]) of
cardiomyocytes was tested in experiments involving heart
treatment with KCl/P-1075/DNP or P-1075/pyruvate. How-ever, we found no evidence to support this hypothesis.
Another attractive possibility was a role of [Ca2 +] as a critical
factor. In a beating heart, [Ca2 +] fluctuates between 10 7 M
in diastole and 10 5 M in a systolic peak [45]. In mitochon-
dria, [Ca2 +] fluctuations follow changes of [Ca2 +] in the
surrounding cytoplasm, although they are never greater than
in cytoplasm [29]. Therefore, it is plausible that high systolic
cytosolic or mitochondrial [Ca2 +] promotes the uncoupling
effect of P-1075. Potassium arrest and calcium channel
blockers prevented [Ca2 +] transients, decreased mean
[Ca2 +] in intact rat hearts [44] and eliminated P-1075-
induced uncoupling. However, lack of the effects of calcium
channel openers and isoproterenol in the KCl-arrested hearts
argues against [Ca2 +] being a crucial factor in the P-1075
interaction with m-KATP.
4.4. Effects P-1075 on DW in isolated liver mitochondria
Direct mitochondrial effect of P-1075 was demonstrated
in isolated rat liver mitochondria. P-1075 depolarized DW by
approximately 14 mV in the presence of K+ and MgATP,
while glibenclamide completely reversed this effect. Al-
though the effect was relatively small, it was of a magnitude
similar to that observed for other KATP openers on isolated rat
liver and heart mitochondria [12,13,17] and demonstrated the
possibility of mitochondrial uncoupling by P-1075. In agree-
ment with our data, Oldenburg et al. recently demonstrated
that P-1075 activated K+ fluxes, with a 10-fold higher
potency than diazoxide, in liposomes containing reconsti-
tuted mitochondrial fraction, and increased reactive oxygen
species-dependent fluorescence in isolated rabbit cardiomyo-
cytes, which is consistent with ability of P-1075 to activate m-
KATP [46].5. Conclusions
A drastic difference in metabolic effects produced by P-
1075 in depolarized and polarized/hyperpolarized hearts
has a great implication to the interpretation of the results
obtained in non-beating cardiomyocytes and isolated mito-
chondria. This implies that metabolic consequences of
activation of sarcolemmal and putative mitochondrial KATP
may be different, depending on the polarization state of
cardiomyocyte plasma membrane. Furthermore, we cannot
exclude that depolarization of the endothelial cells and/or
nerve endings is also important because it may change
release of endogenous norepinephrine, nitric oxide, endo-
thelins and other factors.Acknowledgements
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